Can-Fite Biopharma To Pursue Global Licensing And Strategic Partnerships Using Its Phase IIa Pancreatic Cancer Results

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced its participation in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany, with additional digital partnering sessions scheduled for November 17–18. BIO-Europe 2026.

Dr. Sari Fishman, Vice President of Business Development, will represent Can-Fite at the conference, focusing on potential licensing agreements, co-development arrangements, commercialization partnerships, and other strategic transactions aimed at unlocking the commercial value of the Company's advanced clinical pipeline.

Can-Fite enters BIO-Europe following a series of clinical and intellectual property developments that have strengthened its portfolio and expanded potential partnering opportunities across multiple therapeutic areas.

Key assets and partnering opportunities include:

• Namodenoson – Pancreatic Cancer: Final positive Phase IIa results, presented at ESMO 2026, demonstrated a favorable safety profile and encouraging exploratory survival findings in heavily pretreated patients, supporting further clinical development.

• Namodenoson – Liver Cancer: An ongoing pivotal Phase III study in advanced hepatocellular carcinoma (HCC), with longer-than-anticipated blinded overall survival observed across the study population. An interim analysis is planned.

• Piclidenoson – Psoriasis: A pivotal Phase III program that has reached its prespecified interim analysis stage, with results expected in the first quarter of 2027.

• Namodenoson – MASH: An ongoing Phase IIb clinical development program targeting a significant global market opportunity.

• Piclidenoson – Lowe Syndrome: A rare disease development program supported by a collaboration with Fondazione Telethon and recently strengthened by a Eurasian patent allowance covering Lowe syndrome and Dent disease 2.

Can-Fite has already established multiple regional licensing agreements, generating approximately $20 million in upfront and milestone payments to date, with the potential for additional milestones and royalties. The Company intends to build on this commercial track record by pursuing additional regional and broader strategic partnerships.